Blaschkoid, Zosteriform Linear Lichen Sclerosus et Atrophicus

Abstract

1. Sardella A. An up-to-date view on burning mouth syndrome. Minerva Stomatol. 2007;56:327-40. 2. Zakrzewska JM, Forssell H, Glenny M. Interventions for the treatment of burning mouth syndrome. Cochrane Database Syst Rev. 2005;25:CD002779. 3. Minguez Serra MP, Salort Llorca C, Silvestre Donat FJ. Pharmacological treatment of burning mouth syndrome: A review and update. Med Oral Patol Oral Cir Bucal. 2007;12:299-304. 4. Foster TS. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy. Diabetes Educ. 2007;33:111-7. 5. Fermiano F, Gombos F, Scully C. Burning mouth syndrome: the efficacy of lipoic acid on subgroups. J Eur Acad Dermatol Venereol. 2004;18:676-8. 6. Fermiano F, Gombos F, Scully C. Burning Mouth Syndrome: open trial of psychotherapy alone, medication with alphalipoic acid (thioctic acid), and combination therapy. Med Oral.2004;9:8-13. 7. Fermiano F, Scully C, Gombos F. Idiopathic dysgeusia; an open trial of alpha lipoic acid (ALA) therapy. Int J Oral Maxillofac Surg. 2002;31:625-8. 8. Fermiano F. Burning mouth syndrome (BMS): an open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other therapies. Minerva Stomatol. 2002;51:405-9. 9. Fermiano F, Scully C. Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med. 2002;31:267-9. 10. Fermiano F, Gombos F, Scully C, Busciolano M, De Luca P. Burning mouth syndrome (BMS): controlled open trial of the efficacy of alpha-lipoic acid (thioctic acid) on symptomatology. Oral Dis. 2000;6:274-7. without any improvement in symptoms. Two patients tested positive for antinuclear antibodies and 1 of these, diagnosed with systemic lupus, also tested positive for anti-Ro antibodies. Of all the patients treated, only 3 showed a mild improvement. The remaining patients showed no response to treatment. In the case series presented here, response was limited, as only 3 out of 10 patients reported a mild improvement in symptoms. Although this study cannot provide definitive conclusions, the results would seem to reject the hypothesis of the usefulness of a-lipoic acid in the treatment of BMS, as indicated in the systematic review published by the Cochrane library in 2005.2 Rigorous clinical trials would therefore be needed to demonstrate whether or not this treatment is effective.